|
|
Post by dictatorsaurus on Nov 22, 2016 18:10:33 GMT -5
So Dr's now prescribe drugs depending on the stock price? I thought I heard it all but you guys have an infinite well of humorous excuses. I believe the reference was to MNKD's cash situation and the theory (which I also subscribed to) that some doctor's would be hesitant to prescribe a new drug from a company that was in a precarious financial position. Sorry I just don't buy it. To assume Dr's are closely intune with the financial position of a drug maker and make patient related decisions based on that makes no sense. Thousands of drugs are out there and Dr's are very busy professionals to be reading proboards or listening to conference calls. Even under the Sanofi umbrella the sales were abysmal. Were they worried about the cash position back then too? Afrezza is still virtually unknown both to physicians and patients. I stopped counting long time ago how many PWD I asked about Afrezza and they looked at me like I was speaking some sort of alien language. |
|
|
|
Post by sportsrancho on Nov 22, 2016 18:33:36 GMT -5
Afrezza is still virtually unknown both to physicians and patients. I stopped counting long time ago how many PWD I asked about Afrezza and they looked at me like I was speaking some sort of alien language.
Very true! I can't figure out how they would know unless they follow Diabetic Hands on Twitter. Or have gone on a JDRF walk. Heard if from Laura K, or from a friend.
|
|
|
|
Post by letitride on Nov 22, 2016 19:35:39 GMT -5
When I have a vested doctor tell me that we are likely to lose our money after consulting with a prescribing endo about afrezza because big pharma dosent want us on the market, I know weve got the right stuff. Matt and Mike are doing a fine job of righting the ship. The only thing needed now is PWD putting some wind in the sails. Its time to let them know they can Just Breathe, and be healthier for it.
|
|
|
|
Post by sportsrancho on Nov 22, 2016 19:49:20 GMT -5
When I have a vested doctor tell me that we are likely to lose our money after consulting with a prescribing endo about afrezza because big pharma dosent want us on the market, I know weve got the right stuff. Matt and Mike are doing a fine job of righting the ship. The only thing needed now is PWD putting some wind in the sails. Its time to let them know they can Just Breathe, and be healthier for it. I've got people on Twitter asking how to get their kids in the trials. This is going to be huge for kids! For everyone, but I have a special place in my heart for them and what their parents go through. |
|
|
|
Post by mnholdem on Nov 22, 2016 20:15:11 GMT -5
Amen to that! Michael Castagna is on record as having stated that, for him, there can be no greater priority than to get Afrezza approved for children.
|
|
|
|
Post by mnkdfann on Nov 22, 2016 23:38:15 GMT -5
Very true! I can't figure out how they would know unless they follow Diabetic Hands on Twitter. Or have gone on a JDRF walk. Heard if from Laura K, or from a friend. Or seen the recent morning / afternoon television news spots. Or the ad in the MLB playoff programs. Or the spread in Diabetes Health Monitor. Etc. Okay, none of the above advertising to date has been that great but surely combined it all should have touched millions of eyeballs and had SOME effect by now. |
|
|
|
Post by isler45 on Nov 23, 2016 1:55:06 GMT -5
Even if a few hundred people contacted an endo after seeing the MLB ads, doesn't it take several months to get an appointment?
|
|
|
|
Post by sweedee79 on Nov 23, 2016 9:06:18 GMT -5
My gut feeling after the conference call was that we wouldn't see a dramatic increase in scripts until January. I don't remember the specifics, but Mike made some comments to that effect. He noted waited until then to hire additional sales people. I would be happy to see increases before then, but I am not betting on it. More relative to the reason cited that we would see an increase this week, I do think that endos would hesitate to prescribe a drug to a new patient if they thought it would be pulled from the market. That said, I doubt that many endos were listening to the conference call. As stated above, it's up to the sales team to convince them that Afrezza will be on the market for the long term. My gut feeling is that things are being worked on and put in place... and that we wont see a dramatic uptake in scripts until we are able to do some substantial DTC ads .. and it sounded like that would start in the first quarter of next year.. until then the increase in scripts will be slow and steadily upward IMO .. I glance at the script numbers but don't take it all that seriously right now.. my expectations are in line with what we have been able to accomplish with the money we have.. Mike has done a great job creating awareness in the medical and patient community thru JDRF walks... reps.. twitter.. etc.. and also talking to insurance companies .. progress is being made ... 2017 will be our year .. the company will need more cash to get this all done.... and I trust they are working on that also .. have a wonderful Thanksgiving everyone... !!!! |
|
|
|
Post by dictatorsaurus on Nov 23, 2016 10:23:59 GMT -5
My gut feeling after the conference call was that we wouldn't see a dramatic increase in scripts until January. I don't remember the specifics, but Mike made some comments to that effect. He noted waited until then to hire additional sales people. I would be happy to see increases before then, but I am not betting on it. More relative to the reason cited that we would see an increase this week, I do think that endos would hesitate to prescribe a drug to a new patient if they thought it would be pulled from the market. That said, I doubt that many endos were listening to the conference call. As stated above, it's up to the sales team to convince them that Afrezza will be on the market for the long term. My gut feeling is that things are being worked on and put in place... and that we wont see a dramatic uptake in scripts until we are able to do some substantial DTC ads .. and it sounded like that would start in the first quarter of next year.. until then the increase in scripts will be slow and steadily upward IMO .. I glance at the script numbers but don't take it all that seriously right now.. my expectations are in line with what we have been able to accomplish with the money we have.. Mike has done a great job creating awareness in the medical and patient community thru JDRF walks... reps.. twitter.. etc.. and also talking to insurance companies .. progress is being made ... 2017 will be our year .. the company will need more cash to get this all done.... and I trust they are working on that also .. have a wonderful Thanksgiving everyone... !!!! Initially we were under the assumption they had 70 sales reps, then 60, then we found out they had 42 completely useless temps. It wouldn't be an exaguration to say they hired mall booth quality reps. They did not say they will start an extensive ad campaign. They said ads will start and based on the cash position we can be certain they will be on a very small scale. Which will yield the same results as all the other ads. Which is zero sales. I don't understand how you can say you don't take current script numbers seriously. This is same discussion we were all having two years ago. It seems like salvation is always around the corner, and that nothing in its current depressing state is relevant. Afrezza needs to be sold off to succeed. But unfortunately I don't think any big pharma would want to touch it now, despite what Twitter says! |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 23, 2016 10:39:56 GMT -5
Big pharma would like to see Afrezza sold and buried. Not going to happen.
|
|
|
|
Post by dictatorsaurus on Nov 23, 2016 10:56:42 GMT -5
Big pharma would like to see Afrezza sold and buried. Not going to happen. Big pharma would like to see all of its competitor drugs burried. Any proof Afrezza is being targeted any differently or unfairly? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 23, 2016 11:07:48 GMT -5
Big pharma would like to see Afrezza sold and buried. Not going to happen. Big pharma would like to see all of its competitor drugs burried. Any proof Afrezza is being targeted any differently or unfairly? The incessant negative articles and posts such as yours demonstrates the fear Afrezza has created among big pharmaceuticals. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 23, 2016 11:08:08 GMT -5
Big pharma would like to see Afrezza sold and buried. Not going to happen. I dont think so. They have their own set of issues and they could care less of mannkind. All diabetes related SNY , LLY , NVO have collectively lost 60 billion in market cap in the last few months. so as per you, big pharma is against them too? Edit: ycharts.com/companies/NVO/market_capNVO themselves lost 65 billion in market cap |
|
|
|
Post by sweedee79 on Nov 23, 2016 11:13:24 GMT -5
Even if a few hundred people contacted an endo after seeing the MLB ads, doesn't it take several months to get an appointment? For medicare patients it absolutely does .... the first time it took us 5 months... now we are working on it again and still not sure if its going to work out this year... or next for that matter .. It depends on how much Express Scripts will pay.. whether or not its tier 3 or tier 4 .. If its tier 4 dad says he wont be able to afford it ..Medicare patients have insurance plans they have to pay for as well.. My parents pay out 600$ a month for part B, a medical supplement and Part D insurance .so health care gets very expensive in general even for medicare patients who paid into it all of their lives.. Finding a cooperative doc can be hard too, it has been for us. So this could absolutely be holding up script numbers..
Also for some reason part d plans have decided they aren't covering ANY insulin very well.. all are tier 3 or 4 .. not sure what this is all about .. my guess is the cost of insulin now days.. and soon we will be competing with a generic or biosimilar form of insulin which I believe insurance companies will be more receptive to. I still think the price of Afrezza is an issue.. it is still in fact more expensive than Novolog and Humalog .. and from what Ive seen requires a larger dose in many cases.. and also you can take a larger dose with reduced risk of hypo for a better A1C as well as taking more corrective doses which is really great if you can afford all of it.
Patients now days are having to make choices between their best health and what they can afford... In any case, Afrezza is the best insulin on the market hands down.. MNKD needs to consider our market and demographic which I'm sure they are doing .. It would be nice if it were an affordable medication for all if that is possible (T1,T2 and children)... even a slight decrease in price would help make it more competitive and accessible. JMHO
|
|
|
|
Post by dictatorsaurus on Nov 23, 2016 11:19:29 GMT -5
Big pharma would like to see all of its competitor drugs burried. Any proof Afrezza is being targeted any differently or unfairly? The incessant negative articles and posts such as yours demonstrates the fear Afrezza has created among big pharmaceuticals. The only thing that's demonstrated is your arrogance despite all the facts. You live in La La land where everyone is conveining conspiring against Afrezza. I have news for you. No one even knows about Afrezza, let alone has an opinion or a stance towards it. I can easily dig up past threads you started declaring victory and aspirations. How's that 54 cents a share working out for you? It's not working out too good for me, that's for sure. |
|
